使用非亲属脐带血进行第一次或第二次移植而不使用ATG调理方案治疗小儿骨髓衰竭疾病的结果

IF 2.1 4区 医学 Q3 HEMATOLOGY
Xia Chen , Fang Liu , Yuanyuan Ren , Luyang Zhang, Yang Wan, Wenyu Yang, Xiaojuan Chen, Li Zhang, Yao Zou, Yumei Chen, Xiaofan Zhu, Ye Guo
{"title":"使用非亲属脐带血进行第一次或第二次移植而不使用ATG调理方案治疗小儿骨髓衰竭疾病的结果","authors":"Xia Chen ,&nbsp;Fang Liu ,&nbsp;Yuanyuan Ren ,&nbsp;Luyang Zhang,&nbsp;Yang Wan,&nbsp;Wenyu Yang,&nbsp;Xiaojuan Chen,&nbsp;Li Zhang,&nbsp;Yao Zou,&nbsp;Yumei Chen,&nbsp;Xiaofan Zhu,&nbsp;Ye Guo","doi":"10.1016/j.bcmd.2023.102793","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span>Unrelated umbilical cord blood transplantation<span> (UCBT) for bone marrow failure (BMF) disorders using conditioning regimens without Anti-Thymocyte Globulin (ATG) has been used as an alternative transplantation for emerging patients without matched-sibling donors. Experience with this transplant modality in children is limited, especially as a secondary </span></span>treatment for transplant failure patients.</p></div><div><h3>Procedure</h3><p><span><span>We retrospectively reviewed 17 consecutive bone marrow failure patients who underwent unrelated umbilical cord blood transplantation in our center and received conditioning regimens of Total Body Irradiation (TBI) or </span>Busulfan<span> (BU) + Fludarabine (FLU) + </span></span>Cyclophosphamide (CY).</p></div><div><h3>Results</h3><p>Among the 17 BMF patients, 15 patients were treated with first cord blood transplantation and another 2 with secondary cord blood transplantation because of graft failure<span> after first haploidentical stem cell transplantation at days +38 and +82.</span></p><p><span>All patients engrafted with a median donor cell chimerism of 50 % at days +7 (range, 16 %–99.95 %) and finally rose to 100 % at days +30. Median time to neutrophil </span>engraftment<span><span> was 19 days (range, 12–30) and time to platelet engraftment was 32 days (range, 18–61). Pre-engraftment syndrome (PES) was found in 16 patients (94.11 %, 16/17). Cumulative incidence of grades II to IV acute GVHD was 58.8 % (95 % CI: 32.7–84.9 %), and 17.6 % (95 % CI: 2.6–37.9 %) of patients developed </span>chronic GVHD. The 3-year overall survival (OS) and failure-free survival (FFS) rates were 92.86 ± 6.88 %.</span></p></div><div><h3>Conclusion</h3><p>UCBT is an effective alternative treatment for bone marrow failure pediatric patients. TBI/BU + FLU + CY regimen ensure a high engraftment rate for unrelated umbilical cord blood transplantation, which overcomes the difficulty of graft failure. Secondary salvage use of cord blood transplantation may still be useful for patients who have failed after other transplantation.</p></div>","PeriodicalId":8972,"journal":{"name":"Blood Cells Molecules and Diseases","volume":"104 ","pages":"Article 102793"},"PeriodicalIF":2.1000,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outcome of first or second transplantation using unrelated umbilical cord blood without ATG conditioning regimen for pediatric bone marrow failure disorders\",\"authors\":\"Xia Chen ,&nbsp;Fang Liu ,&nbsp;Yuanyuan Ren ,&nbsp;Luyang Zhang,&nbsp;Yang Wan,&nbsp;Wenyu Yang,&nbsp;Xiaojuan Chen,&nbsp;Li Zhang,&nbsp;Yao Zou,&nbsp;Yumei Chen,&nbsp;Xiaofan Zhu,&nbsp;Ye Guo\",\"doi\":\"10.1016/j.bcmd.2023.102793\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p><span>Unrelated umbilical cord blood transplantation<span> (UCBT) for bone marrow failure (BMF) disorders using conditioning regimens without Anti-Thymocyte Globulin (ATG) has been used as an alternative transplantation for emerging patients without matched-sibling donors. Experience with this transplant modality in children is limited, especially as a secondary </span></span>treatment for transplant failure patients.</p></div><div><h3>Procedure</h3><p><span><span>We retrospectively reviewed 17 consecutive bone marrow failure patients who underwent unrelated umbilical cord blood transplantation in our center and received conditioning regimens of Total Body Irradiation (TBI) or </span>Busulfan<span> (BU) + Fludarabine (FLU) + </span></span>Cyclophosphamide (CY).</p></div><div><h3>Results</h3><p>Among the 17 BMF patients, 15 patients were treated with first cord blood transplantation and another 2 with secondary cord blood transplantation because of graft failure<span> after first haploidentical stem cell transplantation at days +38 and +82.</span></p><p><span>All patients engrafted with a median donor cell chimerism of 50 % at days +7 (range, 16 %–99.95 %) and finally rose to 100 % at days +30. Median time to neutrophil </span>engraftment<span><span> was 19 days (range, 12–30) and time to platelet engraftment was 32 days (range, 18–61). Pre-engraftment syndrome (PES) was found in 16 patients (94.11 %, 16/17). Cumulative incidence of grades II to IV acute GVHD was 58.8 % (95 % CI: 32.7–84.9 %), and 17.6 % (95 % CI: 2.6–37.9 %) of patients developed </span>chronic GVHD. The 3-year overall survival (OS) and failure-free survival (FFS) rates were 92.86 ± 6.88 %.</span></p></div><div><h3>Conclusion</h3><p>UCBT is an effective alternative treatment for bone marrow failure pediatric patients. TBI/BU + FLU + CY regimen ensure a high engraftment rate for unrelated umbilical cord blood transplantation, which overcomes the difficulty of graft failure. Secondary salvage use of cord blood transplantation may still be useful for patients who have failed after other transplantation.</p></div>\",\"PeriodicalId\":8972,\"journal\":{\"name\":\"Blood Cells Molecules and Diseases\",\"volume\":\"104 \",\"pages\":\"Article 102793\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-08-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cells Molecules and Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1079979623000700\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cells Molecules and Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1079979623000700","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景使用不含抗胸腺细胞球蛋白(ATG)的调理方案治疗骨髓衰竭(BMF)疾病的非相关脐带血移植(UCBT)已被用作没有匹配兄弟姐妹供体的新患者的替代移植。儿童这种移植方式的经验有限,尤其是作为移植失败患者的二次治疗。方法我们回顾性分析了在我中心接受非相关脐带血移植并接受全身照射(TBI)或白消安(BU)+氟达拉滨(FLU)+环磷酰胺(CY)调节方案的连续17例骨髓衰竭患者,15名患者在第+38天和第+82天接受了第一次脐带血移植治疗,另有2名患者在第一次单倍体干细胞移植后因移植物失败而接受了第二次脐血移植治疗。所有患者在第+7天接受了50%的中位供体细胞嵌合体移植(范围为16%-99.95%),最后在第+30天达到100%。中性粒细胞植入的中位时间为19天(范围为12-30),血小板植入的中位数时间为32天(范围:18-61)。16例患者(94.11%,16/17)出现植入前综合征(PES)。II至IV级急性移植物抗宿主病的累计发病率为58.8%(95%CI:32.7-84.9%),17.6%(95%CI:2.6-37.9%)的患者发展为慢性移植物抗逆转录病毒。3年总生存率(OS)和无失败生存率(FFS)分别为92.86±6.88%。TBI/BU+FLU+CY方案确保了非亲缘脐血移植的高植入率,克服了移植失败的困难。脐带血移植的二次抢救性使用可能对其他移植后失败的患者仍然有用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Outcome of first or second transplantation using unrelated umbilical cord blood without ATG conditioning regimen for pediatric bone marrow failure disorders

Background

Unrelated umbilical cord blood transplantation (UCBT) for bone marrow failure (BMF) disorders using conditioning regimens without Anti-Thymocyte Globulin (ATG) has been used as an alternative transplantation for emerging patients without matched-sibling donors. Experience with this transplant modality in children is limited, especially as a secondary treatment for transplant failure patients.

Procedure

We retrospectively reviewed 17 consecutive bone marrow failure patients who underwent unrelated umbilical cord blood transplantation in our center and received conditioning regimens of Total Body Irradiation (TBI) or Busulfan (BU) + Fludarabine (FLU) + Cyclophosphamide (CY).

Results

Among the 17 BMF patients, 15 patients were treated with first cord blood transplantation and another 2 with secondary cord blood transplantation because of graft failure after first haploidentical stem cell transplantation at days +38 and +82.

All patients engrafted with a median donor cell chimerism of 50 % at days +7 (range, 16 %–99.95 %) and finally rose to 100 % at days +30. Median time to neutrophil engraftment was 19 days (range, 12–30) and time to platelet engraftment was 32 days (range, 18–61). Pre-engraftment syndrome (PES) was found in 16 patients (94.11 %, 16/17). Cumulative incidence of grades II to IV acute GVHD was 58.8 % (95 % CI: 32.7–84.9 %), and 17.6 % (95 % CI: 2.6–37.9 %) of patients developed chronic GVHD. The 3-year overall survival (OS) and failure-free survival (FFS) rates were 92.86 ± 6.88 %.

Conclusion

UCBT is an effective alternative treatment for bone marrow failure pediatric patients. TBI/BU + FLU + CY regimen ensure a high engraftment rate for unrelated umbilical cord blood transplantation, which overcomes the difficulty of graft failure. Secondary salvage use of cord blood transplantation may still be useful for patients who have failed after other transplantation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
42
审稿时长
14 days
期刊介绍: Blood Cells, Molecules & Diseases emphasizes not only blood cells, but also covers the molecular basis of hematologic disease and studies of the diseases themselves. This is an invaluable resource to all those interested in the study of hematology, cell biology, immunology, and human genetics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信